The only exception is AR+ salivary duct carcinomas, for which several clinical trials have shown an advantage in using the new generation of nonsteroidal antiandrogens in terms of a higher response rate and a better prognosis and clinical outcome. This evidence concerns the gene AR and salivary duct carcinoma.